nafarelin and Hearing-Loss

nafarelin has been researched along with Hearing-Loss* in 1 studies

Other Studies

1 other study(ies) available for nafarelin and Hearing-Loss

Article	Year
Use of a gonadotropin-releasing hormone agonist analogue for treatment of cyclic auditory dysfunction. Obstetrics and gynecology, 1989, Volume: 74, Issue:3 Pt 2 A patient with cyclic luteal phase high-frequency hearing loss is described. This was documented by pre- and post-menstrual audiograms indicating a 40-dB hearing loss in the luteal phase. This had been long-standing and was resistant to oral contraceptive therapy. A gonadotropin-releasing hormone agonist (nafarelin) was used to inhibit ovarian function and was successful in preventing loss of hearing for the 6-month treatment period. Topics: Adult; Audiometry; Female; Gonadotropin-Releasing Hormone; Hearing Loss; Hearing Loss, High-Frequency; Humans; Luteal Phase; Nafarelin	1989

Article

Year

Use of a gonadotropin-releasing hormone agonist analogue for treatment of cyclic auditory dysfunction.

Obstetrics and gynecology, 1989, Volume: 74, Issue:3 Pt 2

A patient with cyclic luteal phase high-frequency hearing loss is described. This was documented by pre- and post-menstrual audiograms indicating a 40-dB hearing loss in the luteal phase. This had been long-standing and was resistant to oral contraceptive therapy. A gonadotropin-releasing hormone agonist (nafarelin) was used to inhibit ovarian function and was successful in preventing loss of hearing for the 6-month treatment period.

Topics: Adult; Audiometry; Female; Gonadotropin-Releasing Hormone; Hearing Loss; Hearing Loss, High-Frequency; Humans; Luteal Phase; Nafarelin

1989